- Home
- DMLP vs PCRX Comparison
DMLP vs PCRX Comparison
Compare DMLP & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMLP
- PCRX
- Stock Information
- Founded
- DMLP 2003
- PCRX 2006
- Country
- DMLP United States
- PCRX United States
- Employees
- DMLP N/A
- PCRX N/A
- Industry
- DMLP Oil & Gas Production
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- DMLP Energy
- PCRX Health Care
- Exchange
- DMLP Nasdaq
- PCRX Nasdaq
- Market Cap
- DMLP 1.4B
- PCRX 1.2B
- IPO Year
- DMLP N/A
- PCRX 2011
- Fundamental
- Price
- DMLP $27.90
- PCRX $25.12
- Analyst Decision
- DMLP
- PCRX Buy
- Analyst Count
- DMLP 0
- PCRX 9
- Target Price
- DMLP N/A
- PCRX $29.89
- AVG Volume (30 Days)
- DMLP 80.8K
- PCRX 745.0K
- Earning Date
- DMLP 05-08-2025
- PCRX 05-08-2025
- Dividend Yield
- DMLP 11.43%
- PCRX N/A
- EPS Growth
- DMLP N/A
- PCRX N/A
- EPS
- DMLP 2.03
- PCRX N/A
- Revenue
- DMLP $166,824,000.00
- PCRX $702,772,000.00
- Revenue This Year
- DMLP N/A
- PCRX $9.48
- Revenue Next Year
- DMLP N/A
- PCRX $11.31
- P/E Ratio
- DMLP $13.69
- PCRX N/A
- Revenue Growth
- DMLP 12.09
- PCRX 3.08
- 52 Week Low
- DMLP $25.84
- PCRX $11.16
- 52 Week High
- DMLP $34.88
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- DMLP 43.43
- PCRX 48.10
- Support Level
- DMLP $26.97
- PCRX $25.08
- Resistance Level
- DMLP $28.30
- PCRX $27.34
- Average True Range (ATR)
- DMLP 0.71
- PCRX 1.16
- MACD
- DMLP -0.10
- PCRX -0.18
- Stochastic Oscillator
- DMLP 31.21
- PCRX 48.85
About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.